Cardiovalve is an innovative transcatheter valve replacement system designed to treat both mitral and tricuspid anatomies. Delivered transfemorally, it eliminates the need for open-heart surgery, offering a less invasive treatment option. The system provides several key advantages, including a compact profile to minimize ventricular protrusion and reduce the risk of LVOT obstruction, a secure anchoring mechanism, and an enhanced sealing solution to prevent paravalvular leaks.

In December 2021, Cardiovalve was acquired by Venus Medtech, a leader in transcatheter structural heart valvular therapies.